NADAC acquisition cost data for PROLIA 60 MG/ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
| 55513071001 | $1,428.42 | 2022-07-01 | Rx |
Generic: Denosumab | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $350.0M | 284,564 | 182,899 | $1,228.38 |
| 2020 | $369.1M | 286,629 | 185,170 | $1,287.21 |
| 2021 | $439.6M | 316,281 | 202,494 | $1,389.55 |
| 2022 | $546.6M | 362,308 | 229,044 | $1,508.16 |
| 2023 | $673.3M | 403,592 | 255,565 | $1,667.47 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $125.5M | 75,369 | 47,634 |
| New York | $84.8M | 50,391 | 31,351 |
| Florida | $73.0M | 43,743 | 28,434 |
| Texas | $66.3M | 39,619 | 25,113 |
| Pennsylvania | $33.7M | 20,604 | 12,835 |
| New Jersey | $28.9M | 17,273 | 10,703 |
| Georgia | $24.5M | 14,422 | 9,237 |
| Arizona | $19.0M | 11,380 | 7,335 |
| Ohio | $16.7M | 9,995 | 6,383 |
| Hawaii | $15.8M | 9,777 | 5,769 |
| North Carolina | $14.6M | 8,680 | 5,784 |
| Michigan | $11.3M | 6,985 | 4,514 |
| Tennessee | $11.2M | 6,674 | 4,419 |
| Connecticut | $10.8M | 6,399 | 3,998 |
| Illinois | $10.5M | 6,200 | 4,012 |
| Virginia | $10.0M | 5,945 | 3,771 |
| Louisiana | $9.3M | 5,544 | 3,605 |
| Missouri | $9.1M | 5,451 | 3,505 |
| Indiana | $8.1M | 4,764 | 3,281 |
| Nevada | $7.4M | 4,421 | 2,794 |
| Kentucky | $7.1M | 4,208 | 2,786 |
| Massachusetts | $7.0M | 4,254 | 2,754 |
| Alabama | $6.9M | 4,118 | 2,760 |
| Maryland | $6.6M | 3,945 | 2,521 |
| Colorado | $6.4M | 3,781 | 2,465 |
| Washington | $5.6M | 3,410 | 2,250 |
| South Carolina | $5.3M | 3,215 | 2,098 |
| Oklahoma | $4.9M | 2,950 | 1,966 |
| Arkansas | $3.4M | 2,007 | 1,326 |
| Mississippi | $3.1M | 1,837 | 1,214 |
| Kansas | $2.3M | 1,372 | 912 |
| Oregon | $2.2M | 1,391 | 917 |
| Puerto Rico | $2.2M | 1,395 | 956 |
| New Mexico | $2.0M | 1,205 | 822 |
| Iowa | $1.9M | 1,160 | 759 |
| Utah | $1.9M | 1,159 | 784 |
| West Virginia | $1.8M | 1,094 | 762 |
| Wisconsin | $1.3M | 790 | 518 |
| Rhode Island | $1.3M | 806 | 506 |
| Delaware | $1.3M | 764 | 483 |
| Maine | $1.1M | 671 | 434 |
| Minnesota | $1.0M | 640 | 432 |
| Idaho | $914.3K | 560 | 381 |
| Nebraska | $870.8K | 519 | 370 |
| District of Columbia | $799.7K | 472 | 300 |
| Alaska | $774.4K | 481 | 317 |
| New Hampshire | $657.8K | 395 | 263 |
| Montana | $438.1K | 265 | 183 |
| North Dakota | $436.5K | 267 | 176 |
| South Dakota | $328.9K | 197 | 129 |
| Wyoming | $328.0K | 196 | 137 |
| Vermont | $306.6K | 182 | 119 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.